HLS Therapeutics (TSE:HLS) Hits New 12-Month Low – Here’s Why

HLS Therapeutics Inc. (TSE:HLS)’s stock price hit a new 52-week low during trading on Monday . The company traded as low as C$4.20 and last traded at C$4.24, with a volume of 21422 shares trading hands. The stock had previously closed at C$4.36.

HLS Therapeutics Stock Performance

The company has a quick ratio of 1.01, a current ratio of 1.00 and a debt-to-equity ratio of 75.00. The stock has a fifty day moving average of C$4.55 and a 200-day moving average of C$4.60. The stock has a market cap of C$132.92 million, a PE ratio of -13.28 and a beta of -0.02.

HLS Therapeutics (TSE:HLS) last posted its quarterly earnings data on Friday, May 15th. The company reported C($0.10) EPS for the quarter. HLS Therapeutics had a negative net margin of 18.42% and a negative return on equity of 16.54%. The company had revenue of C$17.88 million for the quarter. On average, equities analysts forecast that HLS Therapeutics Inc. will post -0.12 EPS for the current year.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.